Business
Data Presented at International Diabetes Conference Further Demonstrate Benefits of Tandem Diabetes Care Automated Insulin Delivery Technologies
MADRID--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced positive data
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":" MADRID--(BUSINESS WIRE)--\nTandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced positive data presented today on its automated insulin delivery technologies, including data from a study of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology demonstrating increased time in range (70 mg/dL -180 mg/dL) 1 in children ages six to thirteen. In a separate presentation, real-world data was presented on the t:slim X2 insulin pump with Basal-IQ® predictive low glucose technology, showing sustained reductions in sensor time spent below 70 mg/dL and improvements in user satisfaction compared to previous therapy. Data was presented during a corporate symposium at the 13th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Madrid, Spain.\n\n\n“These results align with our vision to establish Tandem as a global company that provides easy-to-use insulin therapy management solutions for improved clinical outcomes to children and adults living with diabetes,” said John Sheridan, president and chief executive officer. “In support of this goal, we plan to submit a regulatory filing with the FDA next month to expand the age indication for t:slim X2 with Control-IQ technology to include patients 6 years of age and older.”\n\n\nControl-IQ Advanced Hybrid Closed Loop Technology Data\n\n\nInternational Diabetes Closed Loop Protocol-5 (DCLP5) Study Results\n\n\nDetails from the Protocol 5 (DCLP5) of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop (iDCL) program, an international consortium of academic centers led by the University of Virginia, were presented by Dr. R. Paul Wadwa, Associate Professor of Pediatrics, at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, and the protocol chair for this trial.\n\n\n“This study demonstrated that in school-aged children with type 1 diabetes, who often struggle with diabetes management for a variety of reasons, use of Control-IQ technology led to improved glucose control during both the day and night,” said Dr. Wadwa. “We are thrilled with these results and are hopeful that this system will ultimately offer a valuable treatment option to benefit children with type 1 diabetes.”\n\n\nThe DCLP5 study is a 16-week close...